Keyphrases
Placebo
100%
Chronic Obstructive Pulmonary Disease
100%
Randomized Double-blind
100%
Placebo-controlled Trial
100%
Double Dummy
100%
Arformoterol
100%
Active-controlled Trial
100%
Salmeterol
50%
Dyspnea
30%
Forced Expiratory Volume in 1 Second (FEV1)
30%
Health Status
20%
Adverse Events
20%
Acute Exacerbation of COPD (AECOPD)
20%
St. George's Respiratory Questionnaire
20%
Dyspnea Score
20%
United States
10%
Pulmonary Function
10%
Female Patients
10%
Metered Dose Inhaler
10%
Tolerability
10%
First Dose
10%
Airway Function
10%
Male Patients
10%
R-enantiomer
10%
Formoterol
10%
Clinic Visits
10%
Respiratory Status
10%
Sustained Improvement
10%
Salmeterol xinafoate
10%
Demographic Composition
10%
Arformoterol Tartrate
10%
Provider Visits
10%
Nebulizer
10%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Chronic Obstructive Lung Disease
100%
Arformoterol
100%
Dyspnea
41%
Salmeterol
41%
Adverse Event
16%
Disease Exacerbation
16%
Health Status
16%
Metered-Dose Inhaler
8%
Tolerability
8%
Nebulizer
8%
Formoterol
8%
Salmeterol Xinafoate
8%